Boulder, Colorado, Physician, Consultant to early stage biotechnology companies, Clinical Assistant Professor of Medicine at the University of Colorado Health Sciences Center, Appointed April 2008 to a four-year term

"Leadership," "priorities," "assessment," "research," "quality care," and "outcomes;" these are words used over and over again when one describes the 20-year medical career of Dr. Gilad Gordon or when he describes his own work of guiding and directing healthcare organizations.

Gordon is president of the ORRA Group, a healthcare consulting company guiding the development of cancer therapies. Gordon was previously Vice President of Medical Affairs of the FeRx, a biotechnology firm and director of clinical research at Ribozyme Pharmaceuticals.

He is currently Clinical Assistant Professor of Medicine at the University of Colorado Health Sciences Center and continues as an attending physician at the Denver VA Hospital. Gordon has authored 41 medical abstracts and 17 publications, and delivered 27 lectures on a variety of medical issues. He has been honored numerous times for his research including by his alma mater, Harvard University, by the American Thoracic Society, and by the American College of Physicians. He holds an undergraduate degree in biochemistry from Harvard, an M.D. from the Harvard University/Massachusetts Institute of Technology Health Science and Technology Program, and an M.B.A. from the University of Washington.  He completed his residency in Internal Medicine at the University of Colorado Health Sciences Center and was a Robert Wood Johnson Clinical Scholar at the University of Washington.

In working with the Foundation, he says his priorities are serving the most people with the dollars available, measuring outcomes and developing a means to prioritize care.

For his own part, Gordon says, "I would hope that I will be able to leave a better place than was here prior to my coming on this board. By this I mean that health care is provided to more people, more efficiently, with better outcomes than before."